September 25, 2020
Robust effects of VP01 in human idiopathic pulmonary fibrosis lung tissue
Media
September 23, 2020
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease
September 23, 2020
Nordic Nanovector ASA – Key information regarding potential repair offering
September 23, 2020
Nordic Nanovector – Private placement successfully completed
September 22, 2020
Digital Therapies Help Frontline Workers Cope
September 21, 2020
Camel-IDS enters next stage with name change to PRECIRIX® and IND approval for CAM-H2 Phase I/II study
September 21, 2020
GenSight Biologics reports new analysis demonstrating statistically significant and clinically meaningful difference between visual outcomes in LUMEVOQ®-treated patients and natural history of Leber Hereditary Optic Neuropathy (LHON)
September 18, 2020
Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes
September 16, 2020
Strongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary Shares
September 15, 2020
GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON)
